RxDoctor Payments Data

Kelley Shackelford, MD

Internal Medicine · Orlando, FLNPI 1083118459

Payments from drug & device makers

$2,837in general payments, 2019–2025

Across 157 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$806
  • AbbVie$399
  • Lilly USA, LLC$273
  • AstraZeneca$252
  • Astellas Pharma US Inc$173
  • Biohaven Pharmaceutical Holding Company Ltd.$128
  • plus $806 from 19 others

What the payments were for

  • Food & beverage$2,837100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,837 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$82,059
Medicare patients
269
Services billed
946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide66$97,031
JardianceEmpagliflozin56$60,023
EliquisApixaban34$39,089
MounjaroTirzepatide29$32,475
FarxigaDapagliflozin Propanediol21$20,980
JanuviaSitagliptin Phosphate14$12,719
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$8,269
SynthroidLevothyroxine Sodium65$6,360
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$3,591
ShingrixVaricella-Zoster Ge/As01b/Pf14$3,555
Rosuvastatin Calcium164$2,239
Atorvastatin Calcium199$2,013
Gabapentin129$1,796
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$1,475
Losartan Potassium126$1,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$806$97,03166 claims
Boehringer IngelheimJardiance$21$60,02356 claims
PfizerEliquis$127$39,08934 claims
Lilly USA, LLCMounjaro$273$32,47529 claims
AstraZenecaFarxiga$252$20,98021 claims
AbbVieSynthroid$399$6,36065 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →